NCT01534949View on ClinicalTrials.gov

Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial

PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Diffuse Large B-Cell Lymphoma
Interventions
BIOLOGICAL

rituximab

375 mg/m2 by intravenous \[IV\] infusion

Trial Locations (1)

Unknown

Samsung Medical Center, Seoul

Sponsors

Lead Sponsor

Celltrion
All Listed Sponsors
lead

Celltrion

INDUSTRY

NCT01534949 - Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial | Biotech Hunter | Biotech Hunter